# LEGAL VICTORY AGAINST BIONTECH Public Statement by K. Koenig, Part 1 of 2 Topic: Success of the Law Firm Rogert & Ulbrich – Why Are Mainstream Media and Independent Media Silent About the Groundbreaking Judgment from Aurich?
My name is Katharina Koenig. Today, I am addressing the public to speak about a massive legal breakthrough that is almost completely ignored in the current reporting. The law firm Rogert & Ulbrich has obtained a groundbreaking partial judgment against BioNTech before the Regional Court of Aurich.
This judgment obliges the manufacturer to provide comprehensive information on a catalog of 32 explosive points. This is not about assumptions, but about the court-ordered disclosure of data on the safety, production, and biological effects of the mRNA preparations, which have been kept under lock and key until now. The catalog of questions for complete clarification: 1. Exact lipid composition:
What is the precise mixing ratio of the four lipids used?
2. Integrity of the mRNA: What portion of the mRNA was intact and what portion fragmented?
3. DNA contamination: Information on residues of plasmid DNA from the manufacturing process.
4. Identity of all excipients: A complete list of all added substances and their purity
. 5. Batch variability: Why do the damage reports differ so drastically between different production numbers?
6. Stability of the mRNA: Documentation on degradation products and their potential toxicity.
7. Organ biodistribution: Exactly where do the particles (LNPs) accumulate in the human body?
8. Duration of spike production: Over what period do the cells produce the protein after injection?
9. Quantification of the spike protein: How high is the concentration of the produced protein in the bloodstream?
10. Cell specificity: Into which cell types does the mRNA preferentially enter?
11. Barrier penetration: Data on passage of the blood-brain barrier and the placenta.
12. Comprehensive suspicion reports: All reports of side effects available to the manufacturer worldwide.
13. Severity analysis: Details on the intensity and duration of the reported health damages.
14. Cardiovascular risks: Specific data on myocarditis, heart attacks, and strokes.
15. Neurological disorders: Documentation on paralysis, nerve damage, and autoimmune processes.
16. Death case documentation: All reports in temporal proximity to the administration of the vaccine.
17. Long-term toxicity: Safety data from observational studies over a period of several years.
18. Individual patient data: Anonymized individual data of the study participants from the original approval phases.
19. Exclusion analyses: Why were certain participants removed from the final study evaluation?
20. Placebo unblinding: Why was the control group vaccinated prematurely, complicating long-term comparisons?
21. Infection transmission: Was there scientific proof of protection for third parties available at market launch?
22. Interaction studies: Findings on interactions with other medications or vaccines.
23. Warning history: From what point in time did the manufacturer have information on specific risks?
24. Authority correspondence: Complete disclosure of communication with the PEI and the EMA.
25. Safety reports (PSURs): All regular status reports submitted to the supervisory authorities.
26. Liability provisions: According to the contracts, who bears the financial responsibility for damages incurred?
27. Reverse transcription: Studies on the possible integration of mRNA sequences into human DNA.
28. Antibody-dependent enhancement (ADE): Risk assessment of a possible worsening of infections.
29. Reproductive toxicity: Data on the impact on fertility and the female cycle. #ichwerdezendiert #Freiemedien #Gatekeeper #SieggegenBionTech
Rate this translation: